LA JOLLA, Calif., Feb. 28, 2018 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
leading the discovery and development of innovative medicines
targeting microRNAs, today announced it will provide fourth quarter
and year-end 2017 financial results and corporate highlights on
Wednesday, March 7, 2018 after the
market closes.
Regulus will host a conference call and webcast on March 7, 2018 at 5:00pm
Eastern Time to discuss fourth quarter 2017 financial
results and provide a general business update. A live webcast
of the call will be available online at www.regulusrx.com. To
access the call, please dial (877) 257-8599 (domestic) or (970)
315-0459 (international) and refer to conference ID 4794278. To
access the replay of the call, dial (855) 859-2056 (domestic) or
(404) 537-3406 (international), conference ID 4794278. The webcast
and telephone replay will be archived on the Company's website
following the call.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage
biopharmaceutical company focused on discovering and developing
first-in-class drugs targeting microRNAs to treat diseases with
significant unmet medical need. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a well-balanced microRNA therapeutics pipeline complemented by a
rich intellectual property estate to retain its leadership in the
microRNA field. Regulus is advancing several programs in
renal, hepatic, and central nervous systems diseases. Regulus
maintains its corporate headquarters in La Jolla, CA. For more information,
please visit http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the expected ability
of Regulus to undertake certain activities and accomplish certain
goals (including with respect to development and other activities
related to RG-012 or RGLS4326), the projected timeline of clinical
development activities, and expectations regarding future
therapeutic and commercial potential of Regulus' business plans,
technologies and intellectual property related to microRNA
therapeutics and biomarkers being discovered and developed by
Regulus. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. These and other risks
concerning Regulus' financial position and programs are described
in additional detail in Regulus filings with the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/regulus-to-provide-fourth-quarter-and-year-end-2017-financial-results-on-march-7-2018-300606038.html
SOURCE Regulus Therapeutics Inc.